<DOC>
	<DOC>NCT00689481</DOC>
	<brief_summary>The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.</brief_summary>
	<brief_title>Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male or female subjects at least 12 years old and in good general health. Mild to moderate plaquetype psoriasis Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations History of hypercalcemia or of vitamin D toxicity. Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis. Other serious skin disorder or any chronic medical condition that is not well controlled. Use of nonbiologic systemic antipsoriatic therapy or biologic therapy within four weeks of enrollment. Use of topical therapies that have a known beneficial effect on psoriasis, within 2 weeks of enrollment. Systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment. Use of any investigational therapy within 4 weeks of enrollment. Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Plaque-type Psoriasis</keyword>
	<keyword>psoriasis</keyword>
</DOC>